Quick View
Loading...
Dragon Pharma
Estimated Delivery: 12-26 Days (International), 3-6 Days (United States)
Return within 45 Days of purchase. Duties & taxes are non-refundable.
Buy Survodutide Peptide 10 mg by Dragon Pharma at XSteroids. Survodutide is the twincretin that activates GLP-1 and glucagon receptors at the same time, and it is one of the few metabolic peptides studied for liver fat as well as body weight. Dragon Pharma supplies it as a 10 mg lyophilized vial. This guide covers the mechanism, the trial data, survodutide dosage practice and reconstitution.
Survodutide is an investigational drug from Boehringer Ingelheim, and the information below is educational only.
Survodutide, coded BI 456906, is a dual agonist: it acts on the GLP-1 receptor and the glucagon receptor. The concept comes from oxyntomodulin, a natural gut peptide that signals through both receptors, but the molecule itself is built as a glucagon analogue rather than an oxyntomodulin analogue - a distinction the literature notes specifically in comparison with other dual agonists.
Boehringer Ingelheim is developing it as a weight-loss drug, and it is currently in phase 3 study, so it is not an approved medicine.
GLP-1 receptor activation reduces appetite and slows gastric emptying. Glucagon receptor activation raises energy expenditure and increases fat oxidation, which is the part that distinguishes this class from plain GLP-1 drugs. The glucagon arm is also why liver fat is a target: hepatic lipid handling responds to glucagon signalling.
A meta-analysis of three randomised trials covering 1088 patients found that 4 to 11 months of use at 2.4 to 4.8 mg per week produced an average body weight reduction of 7 to 9%, which translates to roughly 9 to 15 kg. In adults with obesity and at-risk MASLD, survodutide was statistically and clinically superior to placebo in reducing MRI-PDFF assessed liver fat content as well as body weight. The phase 3 SYNCHRONIZE-MASLD trial is studying that population further.
Trial dosing is weekly and escalates in steps, because gastrointestinal tolerance is the limiting factor. In research use the amount is measured in micrograms, which means the reconstitution ratio - not the vial size - determines how many units on an insulin syringe match a given dose.
Mix the lyophilized powder with bacteriostatic water, aiming the stream at the vial wall, then swirl gently instead of shaking. Label the vial with the date, keep the solution refrigerated, and treat a punctured multi-dose vial as usable for 28 days.
Survodutide uses GLP-1 plus glucagon. Semaglutide covers GLP-1 only, tirzepatide pairs GLP-1 with GIP, retatrutide adds glucagon to both, and cagrilintide works through amylin receptors instead. Choosing between them is a question of whether the goal is appetite suppression, energy expenditure, or a liver-fat endpoint. Cutting phases that use them often add thermogenics such as Clenbuterol or thyroid support like T3.
Gastrointestinal effects predominate - nausea, vomiting, diarrhoea and reduced appetite - and they are mild to moderate and dose-dependent in the trials reported so far. As an unapproved peptide with an active phase 3 programme, its long-term safety profile is not established, so blood work, hydration and medical oversight belong in any plan. Persistent severe abdominal pain warrants stopping and seeking medical attention.
Store the lyophilized vial in a cool, dry place away from direct light before reconstitution. After mixing with bacteriostatic water, keep the solution refrigerated and use it within the recommended period for peptide solutions. Keep vials out of the reach of children.
At XSteroids you buy the Dragon Pharma Survodutide vials directly from the brand catalog, with secure checkout, US domestic shipping in 3 to 6 days and international delivery in 12 to 26 days. Browse the full range on the Dragon Pharma brand page to complete your metabolic research stack.
Survodutide is a dual GLP-1 and glucagon receptor agonist, a class called a twincretin, developed by Boehringer Ingelheim for weight loss. It is studied for body weight and liver fat, is currently in phase 3 trials, and is not an approved medicine.
GLP-1 receptor activation reduces appetite and slows gastric emptying, while glucagon receptor activation raises energy expenditure and fat oxidation. The glucagon arm also affects liver lipid handling, which is why liver fat is a studied endpoint for this compound in trials.
Trial protocols use weekly administration at 2.4 to 4.8 mg and escalate in steps, because gastrointestinal tolerance is the limiting factor. In research use the amount is measured in micrograms, so the reconstitution ratio determines how many units on a syringe match a dose.
A meta-analysis of three randomised trials with 1088 patients found an average reduction of 7 to 9% of body weight over 4 to 11 months at 2.4 to 4.8 mg per week, which translates to roughly 9 to 15 kg depending on the starting body weight of the patient.
Mix the powder with bacteriostatic water, aiming the stream at the vial wall, then swirl gently rather than shaking. Label the vial with the reconstitution date, keep the solution refrigerated, and treat a punctured multi-dose vial as usable for 28 days.
Gastrointestinal effects predominate: nausea, vomiting, diarrhoea and reduced appetite, described as mild to moderate and dose-dependent in reported trials. Its long-term safety profile is not established, because the drug is still unapproved and remains in phase 3 testing today for obesity and liver disease.
You can buy Survodutide Peptide 10 mg vials by Dragon Pharma online at XSteroids. The store offers secure checkout, US domestic shipping in 3 to 6 days and international delivery in 12 to 26 days. Add the vial to your cart on this page. All orders ship with tracking.
Loading...
Your cart is currently empty. Let us assist you in finding the right product